Efficacy and Safety of 30-Mg Fimasartan for the Treatment of Patients With Mild to Moderate Hypertension: An 8-Week, Multicenter, Randomized, Double-Blind, Phase III Clinical Study-Reference-Cited by-同舟云学术

Efficacy and Safety of 30-Mg Fimasartan for the Treatment of Patients With Mild to Moderate Hypertension: An 8-Week, Multicenter, Randomized, Double-Blind, Phase III Clinical Study

Published:2014-10 Issue:10 Volume:36 Page:1412-1421
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Youn Jong-Chan,Ihm Sang-Hyun,Bae Jang-Ho,Park Seong-Mi,Jeon Dong Woon,Jung Byung-Chun,Park Tae Ho,Lee Nae Hee,Song Jong-Min,Yoon Young Won,Shin Eun Seok,Sung Ki Chul,Jung In Hyun,Pyun Wook Bum,Joo Seung-Jae,Park Woo Jung,Shin Jin Ho,Kang Seok-Min

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference13 articles.

1. Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist;Chi;Biol Pharm Bull,2013

2. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers;Shin;J Cardiovasc Pharmacol,2011

3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects;Chi;Am J Cardiovasc Drugs,2011

4. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean patients with hypertension: findings from two Phase II, randomized, double-blind, placebo-controlled studies;Lee;Clin Ther,2012

5. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension;Lee;Clin Ther,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood Pressure–lowering Effect of Fimasartan Versus Comparators: A Cross-inference With a Systematic Review and Meta-analysis Through a Quality-management System;Clinical Therapeutics;2023-05

Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study

;Drug Design, Development and Therapy;2020-04

Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study)

;Drug Design, Development and Therapy;2020-01

4. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial;Trials;2019-07-01

5. Novel Medical Treatments for Hypertension and Related Comorbidities;Current Hypertension Reports;2018-08-25